5 hours ago
2
Brendan Coffey, The Motley Fool
Thu, June 4, 2026 astatine 11:10 AM CDT 6 min read
Diabetes absorption is evolving rapidly arsenic the manufacture innovates to dainty the much than 40 cardinal Americans with benignant 1 oregon benignant 2 diabetes. Deciding betwixt 2 leaders successful monitoring and treatment, DexCom (NASDAQ:DXCM) and Insulet (NASDAQ:PODD), requires a adjacent look astatine their maturation and valuation.
DexCom focuses connected continuous glucose monitoring, portion Insulet specializes successful wearable insulin pumps. Both companies are leaders successful their respective niches, but they code antithetic aspects of the aforesaid chronic condition. This examination evaluates their financials and marketplace positions to find which banal offers a much compelling accidental today.
The lawsuit for DexCom
DexCom focuses connected continuous glucose monitoring (CGM) systems that let radical with diabetes to way glucose levels successful existent clip without predominant fingersticks. The institution operates wrong the broader healthcare assemblage and sells its products successful astir 52 countries. Certain organisation agreements accounted for 10% oregon much of full gross successful 2025, and specified lawsuit attraction adds a furniture of hazard to the business.
In FY 2025, gross reached astir $4.7 billion, up 15.6% from the erstwhile year. The institution reported nett income of astir $836.3 cardinal for 2025, up $168.8 cardinal from the anterior year. This resulted successful a nett borderline of 17.9%, which measures however overmuch nett a institution kept from each dollar of full sales.
The institution has a debt-to-equity ratio of astir 0.5x, which compares full indebtedness to shareholders’ equity. Free currency travel for the twelvemonth was astir $1.1 billion, calculated by subtracting superior expenditures from currency generated by operations. That’s astir capable to wage disconnected its $1.38 cardinal successful full indebtedness if absorption wanted to.
The lawsuit for Insulet
Insulet specializes successful the Omnipod system, a tubeless insulin pump that simplifies insulin transportation for radical with diabetes via a wearable pod. The institution serves much than 600,000 planetary customers and has successfully expanded its beingness into astir 25 countries. It relies connected 3 large distributors, each accounting for 10% oregon much of revenue, and lawsuit attraction similar this adds a furniture thiof hazard to the business.
During FY 2025, the institution generated gross of conscionable implicit $2.7 billion, representing a 30.9% increase. Net income for the fiscal twelvemonth was astir $354.4 million, contempt the competitory quality of the aesculapian exertion market. This produced a nett borderline of adjacent to 10.4% for the period, reflecting its existent operational scale.
English (CA) · 
English (US) · 
Spanish (MX) ·